114 related articles for article (PubMed ID: 38614414)
1. A fully biodegradable spherical nucleic acid nanoplatform for self-codelivery of doxorubicin and miR122 for innate and adaptive immunity activation.
Jiang MC; Fang ZL; Zhang JY; Ma W; Liao LF; Yu CY; Wei H
Acta Biomater; 2024 May; 180():407-422. PubMed ID: 38614414
[TBL] [Abstract][Full Text] [Related]
2. A Sodium Alginate-Based Multifunctional Nanoplatform for Synergistic Chemo-Immunotherapy of Hepatocellular Carcinoma.
Huang C; Xie T; Liu Y; Yan S; OuYang F; Zhang H; Lei L; He D; Wei H; Yu CY
Adv Mater; 2023 Aug; 35(33):e2301352. PubMed ID: 37216573
[TBL] [Abstract][Full Text] [Related]
3. A multivalent polyphenol-metal-nanoplatform for cascade amplified chemo-chemodynamic therapy.
Li S; Zhao Y; Ma W; Wang D; Liu H; Wang W; Peng D; Yu CY; Wei H
Acta Biomater; 2024 Jan; 173():389-402. PubMed ID: 37967695
[TBL] [Abstract][Full Text] [Related]
4. EGFR-targeted multifunctional polymersomal doxorubicin induces selective and potent suppression of orthotopic human liver cancer in vivo.
Fang Y; Yang W; Cheng L; Meng F; Zhang J; Zhong Z
Acta Biomater; 2017 Dec; 64():323-333. PubMed ID: 29030307
[TBL] [Abstract][Full Text] [Related]
5. Construction of a biodegradable, versatile nanocarrier for optional combination cancer therapy.
Wen J; Lv Y; Xu Y; Zhang P; Li H; Chen X; Li X; Zhang L; Liu F; Zeng W; Sun S
Acta Biomater; 2019 Jan; 83():359-371. PubMed ID: 30414486
[TBL] [Abstract][Full Text] [Related]
6. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L
Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690
[TBL] [Abstract][Full Text] [Related]
7. MiR-375 delivered by lipid-coated doxorubicin-calcium carbonate nanoparticles overcomes chemoresistance in hepatocellular carcinoma.
Zhao P; Wu S; Cheng Y; You J; Chen Y; Li M; He C; Zhang X; Yang T; Lu Y; Lee RJ; He X; Xiang G
Nanomedicine; 2017 Nov; 13(8):2507-2516. PubMed ID: 28577837
[TBL] [Abstract][Full Text] [Related]
8. A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinoma.
Chen X; Ding G; Gao Q; Sun J; Zhang Q; Du L; Qiu Z; Wang C; Zheng F; Sun B; Ni J; Feng Z; Zhu J
PLoS One; 2013; 8(5):e63093. PubMed ID: 23675455
[TBL] [Abstract][Full Text] [Related]
9. MiR-101 and doxorubicin codelivered by liposomes suppressing malignant properties of hepatocellular carcinoma.
Xu F; Liao JZ; Xiang GY; Zhao PX; Ye F; Zhao Q; He XX
Cancer Med; 2017 Mar; 6(3):651-661. PubMed ID: 28135055
[TBL] [Abstract][Full Text] [Related]
10. Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo.
Wei Y; Gu X; Cheng L; Meng F; Storm G; Zhong Z
Acta Biomater; 2019 Jul; 92():196-204. PubMed ID: 31102765
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of NIR-II semiconducting polymer and pH-sensitive doxorubicin-conjugated prodrug for photothermal/chemotherapy.
Yu D; Wang Y; Chen J; Liu S; Deng S; Liu C; McCulloch I; Yue W; Cheng D
Acta Biomater; 2022 Jan; 137():238-251. PubMed ID: 34653697
[TBL] [Abstract][Full Text] [Related]
12. Isoginkgetin synergizes with doxorubicin for robust co-delivery to induce autophagic cell death in hepatocellular carcinoma.
Wang Y; Yi Y; Yao J; Wan H; Yu M; Ge L; Zeng X; Wu M; Mei L
Acta Biomater; 2022 Nov; 153():518-528. PubMed ID: 36152910
[TBL] [Abstract][Full Text] [Related]
13. TPGS-Galactose-Modified Polydopamine Co-delivery Nanoparticles of Nitric Oxide Donor and Doxorubicin for Targeted Chemo-Photothermal Therapy against Drug-Resistant Hepatocellular Carcinoma.
Du Z; Mao Y; Zhang P; Hu J; Fu J; You Q; Yin J
ACS Appl Mater Interfaces; 2021 Aug; 13(30):35518-35532. PubMed ID: 34286569
[TBL] [Abstract][Full Text] [Related]
14. Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib.
Duan W; Liu Y
Drug Des Devel Ther; 2018; 12():2149-2161. PubMed ID: 30034219
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2.
Tu C; Chen W; Wang S; Tan W; Guo J; Shao C; Wang W
J Cell Mol Med; 2019 Nov; 23(11):7190-7199. PubMed ID: 30801960
[TBL] [Abstract][Full Text] [Related]
16. Polymeric Hybrid Nanomicelles for Cancer Theranostics: An Efficient and Precise Anticancer Strategy for the Codelivery of Doxorubicin/miR-34a and Magnetic Resonance Imaging.
Xie X; Chen Y; Chen Z; Feng Y; Wang J; Li T; Li S; Qin X; Wu C; Zheng C; Zhu J; You F; Liu Y; Yang H
ACS Appl Mater Interfaces; 2019 Nov; 11(47):43865-43878. PubMed ID: 31684723
[TBL] [Abstract][Full Text] [Related]
17. Codelivery of doxorubicin and triptolide with reduction-sensitive lipid-polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment.
Wu B; Lu ST; Zhang LJ; Zhuo RX; Xu HB; Huang SW
Int J Nanomedicine; 2017; 12():1853-1862. PubMed ID: 28331310
[TBL] [Abstract][Full Text] [Related]
18. Autophagy inhibition contributes to the synergistic interaction between EGCG and doxorubicin to kill the hepatoma Hep3B cells.
Chen L; Ye HL; Zhang G; Yao WM; Chen XZ; Zhang FC; Liang G
PLoS One; 2014; 9(1):e85771. PubMed ID: 24465696
[TBL] [Abstract][Full Text] [Related]
19. Enhanced doxorubicin delivery to hepatocellular carcinoma cells via CD147 antibody-conjugated immunoliposomes.
Wang J; Wu Z; Pan G; Ni J; Xie F; Jiang B; Wei L; Gao J; Zhou W
Nanomedicine; 2018 Aug; 14(6):1949-1961. PubMed ID: 29045824
[TBL] [Abstract][Full Text] [Related]
20. Fabricating polydopamine-coated MoSe
Chai S; Kan S; Sun R; Zhou R; Sun Y; Chen W; Yu B
Int J Nanomedicine; 2018; 13():7607-7621. PubMed ID: 30510420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
